$REGN
REGENERON PHARMACEUTICALS, INC.

2015 Q1 Form 10-Q Financial Statement

#000153217615000020 Filed on May 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q1
Revenue $869.6M $625.7M
YoY Change 38.97% 42.32%
Cost Of Revenue $42.57M $27.47M
YoY Change 54.95% -1.96%
Gross Profit $827.0M $598.3M
YoY Change 38.24% 45.34%
Gross Profit Margin 95.1% 95.61%
Selling, General & Admin $159.0M $103.2M
YoY Change 54.02% 33.61%
% of Gross Profit 19.22% 17.25%
Research & Development $343.1M $287.4M
YoY Change 19.39% 59.39%
% of Gross Profit 41.49% 48.04%
Depreciation & Amortization $16.03M $11.53M
YoY Change 39.0% 22.57%
% of Gross Profit 1.94% 1.93%
Operating Expenses $502.1M $390.6M
YoY Change 28.54% 51.66%
Operating Profit $283.6M $191.6M
YoY Change 48.02% 25.16%
Interest Expense $6.169M $11.61M
YoY Change -46.88% -0.53%
% of Operating Profit 2.18% 6.06%
Other Income/Expense, Net -$7.030M -$10.68M
YoY Change -34.15% -4.84%
Pretax Income $276.5M $180.9M
YoY Change 52.87% 27.54%
Income Tax $200.5M $112.6M
% Of Pretax Income 72.51% 62.24%
Net Earnings $76.02M $68.31M
YoY Change 11.3% -30.92%
Net Earnings / Revenue 8.74% 10.92%
Basic Earnings Per Share $0.74 $0.69
Diluted Earnings Per Share $0.66 $0.61
COMMON SHARES
Basic Shares Outstanding 102.2M shares 98.71M shares
Diluted Shares Outstanding 114.5M shares 112.2M shares

Balance Sheet

Concept 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $742.0M $648.0M
YoY Change 14.51% 110.39%
Cash & Equivalents $507.9M $461.9M
Short-Term Investments $234.0M $186.0M
Other Short-Term Assets $125.0M $107.0M
YoY Change 16.82% -32.7%
Inventory $133.9M $86.55M
Prepaid Expenses
Receivables $1.016B $801.8M
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.311B $1.871B
YoY Change 23.5% 43.14%
LONG-TERM ASSETS
Property, Plant & Equipment $1.111B $600.9M
YoY Change 84.83% 53.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $483.0M $535.0M
YoY Change -9.72% 54.18%
Other Assets $4.473M $5.340M
YoY Change -16.24% -73.4%
Total Long-Term Assets $1.888B $1.389B
YoY Change 35.88% 43.4%
TOTAL ASSETS
Total Short-Term Assets $2.311B $1.871B
Total Long-Term Assets $1.888B $1.389B
Total Assets $4.199B $3.260B
YoY Change 28.77% 43.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $91.00M $33.00M
YoY Change 175.76% 32.0%
Accrued Expenses $372.0M $205.0M
YoY Change 81.46% 69.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $536.1M $305.1M
YoY Change 75.74% 54.67%
LONG-TERM LIABILITIES
Long-Term Debt $472.0M $530.0M
YoY Change -10.94% 14.97%
Other Long-Term Liabilities $55.56M $11.79M
YoY Change 371.08% 34.24%
Total Long-Term Liabilities $55.56M $11.79M
YoY Change 371.08% 34.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $536.1M $305.1M
Total Long-Term Liabilities $55.56M $11.79M
Total Liabilities $1.227B $1.049B
YoY Change 16.97% 20.64%
SHAREHOLDERS EQUITY
Retained Earnings $292.7M -$27.25M
YoY Change -1174.04% -93.48%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $181.8M
YoY Change
Treasury Stock Shares 2.164M shares
Shareholders Equity $2.971B $2.211B
YoY Change
Total Liabilities & Shareholders Equity $4.199B $3.260B
YoY Change 28.77% 43.25%

Cashflow Statement

Concept 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income $76.02M $68.31M
YoY Change 11.3% -30.92%
Depreciation, Depletion And Amortization $16.03M $11.53M
YoY Change 39.0% 22.57%
Cash From Operating Activities -$101.7M $53.53M
YoY Change -290.05% -37.94%
INVESTING ACTIVITIES
Capital Expenditures -$114.2M -$64.80M
YoY Change 76.23% 205.66%
Acquisitions
YoY Change
Other Investing Activities -$15.30M -$171.4M
YoY Change -91.07% 35.49%
Cash From Investing Activities -$129.5M -$236.2M
YoY Change -45.19% 59.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $76.27M $55.04M
YoY Change 38.57% 324.58%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $90.40M $109.0M
YoY Change -17.03% 845.54%
NET CHANGE
Cash From Operating Activities -$101.7M $53.53M
Cash From Investing Activities -$129.5M -$236.2M
Cash From Financing Activities $90.40M $109.0M
Net Change In Cash -$140.8M -$73.75M
YoY Change 90.93% 47.75%
FREE CASH FLOW
Cash From Operating Activities -$101.7M $53.53M
Capital Expenditures -$114.2M -$64.80M
Free Cash Flow $12.47M $118.3M
YoY Change -89.46% 10.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 regn Debt Conversion
DebtConversion
16700000 USD
CY2014Q4 regn Limitpricepershareforwarrantholderstocloseouthedgeposition
Limitpricepershareforwarrantholderstocloseouthedgeposition
397.75
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000872589
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
REGENERON PHARMACEUTICALS INC
CY2013Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
16100000 USD
CY2014Q1 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
17600000 USD
CY2014Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
56200000 USD
CY2015Q1 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
84100000 USD
CY2014Q4 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
41555000 USD
CY2015Q1 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
44659000 USD
CY2014Q4 regn Accruedsalesrelatedchargesdeductionsandroyalties
Accruedsalesrelatedchargesdeductionsandroyalties
133085000 USD
CY2015Q1 regn Accruedsalesrelatedchargesdeductionsandroyalties
Accruedsalesrelatedchargesdeductionsandroyalties
165511000 USD
CY2014Q1 regn Costofmanufacturing
Costofmanufacturing
16099000 USD
CY2015Q1 regn Costofmanufacturing
Costofmanufacturing
41385000 USD
CY2014Q4 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
15927000 USD
CY2015Q1 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
19342000 USD
CY2014Q4 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
72367000 USD
CY2015Q1 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
48656000 USD
CY2014Q4 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
310938000 USD
CY2015Q1 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
328394000 USD
CY2014Q1 regn Facilityleaseobligationrecognizedduringtheperiod
Facilityleaseobligationrecognizedduringtheperiod
19400000 USD
CY2015Q1 regn Facilityleaseobligationrecognizedduringtheperiod
Facilityleaseobligationrecognizedduringtheperiod
10800000 USD
CY2014Q1 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
401000 shares
CY2015Q1 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
467000 shares
CY2014Q1 regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived
500000000 USD
CY2014Q1 regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million
600000000 USD
CY2015Q1 regn Limitpricepershareforwarrantholderstocloseouthedgeposition
Limitpricepershareforwarrantholderstocloseouthedgeposition
408.00
CY2015Q1 regn Maximumamountofwarrantpayable
Maximumamountofwarrantpayable
24000000 USD
CY2014Q4 regn Maximumreductionofwarrantsheldbywarrantholder
Maximumreductionofwarrantsheldbywarrantholder
493229 shares
CY2015Q1 regn Maximumreductionofwarrantsheldbywarrantholder
Maximumreductionofwarrantsheldbywarrantholder
76749 shares
CY2014Q1 regn Numberofsalesmilestonepaymentsthe Companyreceived
NumberofsalesmilestonepaymentstheCompanyreceived
2
CY2015Q1 regn Numberofsalesmilestonepaymentsthe Companyreceived
NumberofsalesmilestonepaymentstheCompanyreceived
1
CY2014Q1 regn Other Collaboration Revenue
OtherCollaborationRevenue
125312000 USD
CY2015Q1 regn Other Collaboration Revenue
OtherCollaborationRevenue
123846000 USD
CY2014Q1 regn Period For Achieving Sales Target For Milestone Payment Rolling Basis
PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
P12M
CY2015Q1 regn Period For Achieving Sales Target For Milestone Payment Rolling Basis
PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
P12M
CY2015Q1 regn Stockissuedduringperiodconversionofconvertiblenotes
Stockissuedduringperiodconversionofconvertiblenotes
146253 shares
CY2014Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
156962000 USD
CY2015Q1 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
163056000 USD
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
483489000 USD
CY2015Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
462762000 USD
CY2014Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
99508000 USD
CY2015Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
90601000 USD
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
739379000 USD
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1015962000 USD
CY2014Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
121058000 USD
CY2015Q1 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
159444000 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
52251000 USD
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
47904000 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2465008000 USD
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2812573000 USD
CY2014Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-14778000 USD
CY2015Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-163523000 USD
CY2014Q4 us-gaap Assets
Assets
3893979000 USD
CY2015Q1 us-gaap Assets
Assets
4198573000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
2167461000 USD
CY2015Q1 us-gaap Assets Current
AssetsCurrent
2310714000 USD
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
711915000 USD
CY2015Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
717562000 USD
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
81989000 USD
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
73726000 USD
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1551000 USD
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
102000 USD
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
631477000 USD
CY2015Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
643938000 USD
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
14000 USD
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
1551000 USD
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
102000 USD
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
426941000 USD
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
144797000 USD
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1551000 USD
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
88000 USD
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
426941000 USD
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
140658000 USD
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0 USD
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
4139000 USD
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
1128000 USD
CY2015Q1 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
1101000 USD
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
360208000 USD
CY2015Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
392624000 USD
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
251761000 USD
CY2015Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
234257000 USD
CY2014Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
613097000 USD
CY2015Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
627982000 USD
CY2014Q1 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
0 USD
CY2015Q1 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
-2466000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
535608000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
461858000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
648719000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
507907000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-73750000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-140812000 USD
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
70958000 USD
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
71674000 USD
CY2014Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
146773000 USD
CY2015Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
144082000 USD
CY2014Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
27473000 USD
CY2015Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
42570000 USD
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
434178000 USD
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
437610000 USD
us-gaap Costs And Expenses
CostsAndExpenses
871788000 USD
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
537324000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1409112000 USD
CY2014Q4 us-gaap Costs And Expenses
CostsAndExpenses
586526000 USD
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
1995638000 USD
CY2015Q1 us-gaap Costs And Expenses
CostsAndExpenses
586059000 USD
CY2014Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
112581000 USD
CY2011Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
400000000 USD
CY2014Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-5761000 USD
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
58098000 USD
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
51845000 USD
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
103909000 USD
CY2015Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
114318000 USD
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
49235000 USD
CY2015Q1 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
62126000 USD
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
289021000 USD
CY2015Q1 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
289484000 USD
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11530000 USD
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16027000 USD
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.69
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.65
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.47
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.89
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.36
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.46
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.19
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.78
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.98
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.66
CY2014Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.622
CY2015Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.725
CY2014Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.104
CY2014Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
92778000 USD
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
64112000 USD
CY2014Q1 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
117260000 USD
CY2015Q1 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
155569000 USD
CY2014Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0 USD
CY2015Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
91400000 USD
CY2014Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2015Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-942000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
180886000 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
208803000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
389689000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
181823000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
571512000 USD
CY2014Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
189723000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
761235000 USD
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
276523000 USD
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
112581000 USD
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
112452000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
225033000 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
98448000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
323481000 USD
CY2014Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
99628000 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
423109000 USD
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200502000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-14139000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
25534000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
92529000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
321063000 USD
CY2014Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
5761000 USD
CY2015Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
10888000 USD
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
37107000 USD
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-16140000 USD
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15550000 USD
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5932000 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20898000 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-35874000 USD
CY2014Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
3162000 shares
CY2015Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2512000 shares
CY2014Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9879000 shares
CY2015Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9313000 shares
CY2014Q1 us-gaap Interest Expense
InterestExpense
11613000 USD
CY2015Q1 us-gaap Interest Expense
InterestExpense
6169000 USD
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10768000 USD
CY2015Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11398000 USD
CY2014Q4 us-gaap Inventory Net
InventoryNet
128861000 USD
CY2015Q1 us-gaap Inventory Net
InventoryNet
133863000 USD
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
10923000 USD
CY2015Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9644000 USD
CY2014Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
73519000 USD
CY2015Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
83990000 USD
CY2014Q4 us-gaap Liabilities
Liabilities
1329502000 USD
CY2015Q1 us-gaap Liabilities
Liabilities
1227143000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3893979000 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4198573000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
654660000 USD
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
536134000 USD
CY2014Q1 us-gaap Licenses Revenue
LicensesRevenue
7542000 USD
CY2015Q1 us-gaap Licenses Revenue
LicensesRevenue
27837000 USD
CY2014Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
251761000 USD
CY2015Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
234257000 USD
CY2014Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
460154000 USD
CY2015Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
483305000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108954000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
76171000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-236231000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-129481000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
53527000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87502000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
68305000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
96351000 USD
us-gaap Net Income Loss
NetIncomeLoss
164656000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
83375000 USD
us-gaap Net Income Loss
NetIncomeLoss
248031000 USD
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
90095000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
338126000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
76021000 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10676000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
419652000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
188464000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
191562000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
608116000 USD
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
215803000 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
823919000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
283553000 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7030000 USD
CY2013Q4 us-gaap Notes Payable
NotesPayable
0 USD
CY2014Q1 us-gaap Notes Payable
NotesPayable
0 USD
CY2014Q4 us-gaap Notes Payable
NotesPayable
7500000 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
228090000 USD
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
116563000 USD
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
97879000 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3034000 USD
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4473000 USD
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2653000 USD
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4347000 USD
CY2014Q4 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
33651000 USD
CY2015Q1 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
28831000 USD
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
97146000 USD
CY2015Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2185000 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
40855000 USD
CY2015Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
55559000 USD
CY2014Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
5916000 USD
CY2015Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
2358000 USD
CY2014Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3761000 USD
CY2015Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-6006000 USD
CY2014Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
937000 USD
CY2015Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
81000 USD
CY2015Q1 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
124000000 USD
CY2014Q1 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0 USD
CY2015Q1 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
124531000 USD
CY2014Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
63086000 USD
CY2015Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
21192000 USD
CY2014Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
253878000 USD
CY2015Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
95775000 USD
CY2014Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
64822000 USD
CY2015Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
114162000 USD
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
71486000 USD
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
34099000 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
55042000 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
76273000 USD
CY2014Q1 us-gaap Proceeds From Repayments Of Long Term Debt And Capital Securities
ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
-262000 USD
CY2015Q1 us-gaap Proceeds From Repayments Of Long Term Debt And Capital Securities
ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
6738000 USD
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
82469000 USD
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
80456000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
974309000 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1110597000 USD
CY2014Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
CY2015Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
16686000 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
287379000 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
343113000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
216644000 USD
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
292665000 USD
CY2014Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
130508000 USD
CY2015Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
173356000 USD
CY2014Q1 us-gaap Revenues
Revenues
625740000 USD
CY2015Q1 us-gaap Revenues
Revenues
869612000 USD
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
362378000 USD
CY2015Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
544573000 USD
CY2014Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
103227000 USD
CY2014Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
96730000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
199957000 USD
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
144003000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
343960000 USD
CY2014Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
175307000 USD
CY2014 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
519267000 USD
CY2015Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
158991000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
75785000 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
103759000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
2564477000 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
2971430000 USD
CY2014Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
2017732 shares
CY2015Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
2163980 shares
CY2014Q4 us-gaap Treasury Stock Value
TreasuryStockValue
169530000 USD
CY2015Q1 us-gaap Treasury Stock Value
TreasuryStockValue
181817000 USD
CY2013Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
24601000 USD
CY2014Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
25365000 USD
CY2014Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
24781000 USD
CY2015Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
38072000 USD
CY2014Q1 us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
24192000 USD
CY2015Q1 us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
37517000 USD
CY2014Q1 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
23428000 USD
CY2015Q1 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
24226000 USD
CY2014Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13442000 shares
CY2015Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
12292000 shares
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112151000 shares
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114519000 shares
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98709000 shares
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102227000 shares
CY2015Q1 us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued a new standard related to revenue recognition, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which will replace existing revenue recognition guidance. The new standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. To achieve that core principle, an entity must identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when (or as) the entity satisfies the performance obligation. The new standard will be effective for annual and interim reporting periods beginning after December 15, 2016, and early adoption is not permitted. The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. The Company has not yet determined its method of transition and is evaluating the impact that this guidance will have on the Company's financial statements.</font></div></div>
CY2015Q1 us-gaap Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees, and other sales-related deductions. </font></div></div>

Files In Submission

Name View Source Status
0001532176-15-000020-index-headers.html Edgar Link pending
0001532176-15-000020-index.html Edgar Link pending
0001532176-15-000020.txt Edgar Link pending
0001532176-15-000020-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regn-033115x10q.htm Edgar Link pending
regn-20150331.xml Edgar Link completed
regn-20150331.xsd Edgar Link pending
regn-20150331_cal.xml Edgar Link unprocessable
regn-20150331_def.xml Edgar Link unprocessable
regn-20150331_lab.xml Edgar Link unprocessable
regn-20150331_pre.xml Edgar Link unprocessable
regn-ex_101x03312015x10q.htm Edgar Link pending
regn-ex_102x03312015x10q.htm Edgar Link pending
regn-ex_311x03312015x10q.htm Edgar Link pending
regn-ex_312x03312015x10q.htm Edgar Link pending
regn-ex_32x03312015x10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending